Ide-Cel: Real-World Outcomes for Relapsed Refractory Multiple Myeloma
Panelists discuss how ide-cel, a CAR T-cell therapy, demonstrates promising real-world outcomes in patients with relapsed/refractory multiple myeloma, potentially offering a valuable treatment option for this challenging patient population.
EP: 1.Treatment Strategies in Relapsed Refractory Multiple Myeloma
EP: 2.Ide-Cel: Real-World Outcomes for Relapsed Refractory Multiple Myeloma
EP: 3.KarMMa-3: Ide-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma
EP: 4.CARTITUDE-4: Cilta-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma
EP: 5.Patient Case: A 68-Year-Old Woman with Triple Class Exposed Relapsed Refractory Multiple Myeloma
EP: 6.Patient Case: A 67-Year-Old, BCMA-Naïve, Woman with Relapsed Refractory Multiple Myeloma
EP: 7.Sequencing Therapies for Relapsed Refractory Multiple Myeloma: Bispecifics or CAR T-cell Therapy
EP: 8.Bispecific Selection in BCMA-failed Therapy for Relapsed Refractory Multiple Myeloma
EP: 9.Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple Myeloma
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
